Aim: To investigate the effects of Astragalus polysaccharides (APS) on tumor necrosis factor (TNF)-α-induced inflammatory reactions in human umbilical vein endothelial cells (HUVECs) and to elucidate the underlying mechanisms. Methods: HUVECs were treated with TNF-α for 24 h. The amounts of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) were determined with Western blotting. HUVEC viability and apoptosis were detected using cell viability assay and Hoechst staining, respectively. Reactive oxygen species (ROS) production was measured by DHE staining. Monocyte and HUVEC adhesion assay was used to detect endothelial cell adhesive function. NF-κB activation was detected with immunofluorescence. Results: TNF-α (1-80 ng/mL) caused dose-and time-dependent increases of ICAM-1 and VCAM-1 expression in HUVECs, accompanied by significant augmentation of IκB phosphorylation and NF-κB translocation into the nuclei. Pretreatment with APS (10 and 50 µg/mL) significantly attenuated TNFα-induced upregulation of ICAM-1, VCAM-1, and NF-κB translocation. Moreover, APS significantly reduced apoptosis, ROS generation and adhesion function damage in TNF-α-treated HUVECs. Conclusion: APS suppresses TNFα-induced adhesion molecule expression by blocking NF-κB signaling and inhibiting ROS generation in HUVECs. The results suggest that APS may be used to treat and prevent endothelial cell injury-related diseases.
Introduction
Endothelial cell injury is an important cause of serious cardiovascular diseases, such as atherosclerosis, which can cause serious clinical consequences such as myocardial infarction, heart failure and stroke. Accumulated evidence demonstrates that atherosclerosis is closely related to the inflammatory and proliferative responses of the endothelium after injury [1] . During the early stages of atherosclerosis, adhesion molecules, including intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), are secreted by activated endothelial cells in atherosclerotic lesions, stimulating immune cell and monocyte recruitment and migration into the intimal area of the vascular wall [2] . Tumor necrosis factor (TNF)-α, one of the most potent pro-inflammatory cytokines [3] , is critically implicated not only in the induction of endothelial # These authors contributed equally to this work. * To whom correspondence should be addressed.
E-mail lijian@bjhmoh.cn Received 2012-11-07 Accepted 2013-03-14 apoptosis [4] but also in the development and progression of atherosclerotic lesions in humans [5] . Nuclear factor-κB (NF-κB) plays an important role in the transcriptional regulation of inflammatory proteins such as cyclooxygenase-2 (COX-2), ICAM-1, VCAM-1, and E-selectin [6] . NF-κB exists in the cytoplasm of unstimulated cells and is bound to its inhibitory protein, IκBα. IκBα phosphorylation leads to its degradation and the subsequent translocation of NF-κB to the nucleus where it activates target gene transcription. During atherosclerosis, NF-κB functions as a regulator of pro-inflammatory and anti-inflammatory gene transcription and as a regulator of cell survival and proliferation.
Many herbs are used in traditional Chinese medicine. The roots of Astragalus membranaceus (Huangqi) belong to the Fabaceae family, which contains some of the most popular health-promoting herbs in China [7, 8] . Astragalus is a crude drug that has been widely used in traditional Chinese medicine for thousands of years to treat various renal diseases [9] . Polysaccharides from Radix Astragali are a class of macromolecules that have shown strong anti-tumor and anti-1037 www.chinaphar.com Zhu YP et al Acta Pharmacologica Sinica npg glomerulonephritis activities [10, 11] . Studies have also shown that Astragalus polysaccharides (APS) have a beneficial effect on nephrotic syndrome, possess immunopotentiative functions and improve early diabetic nephropathy [8, 12] . However, the effects and molecular mechanisms of APS on endothelial cell protection are far from clear. To address this issue, this study was designed to investigate whether APS can inhibit TNF-α-induced inflammatory reactions in human umbilical vein endothelial cells (HUVECs) and illustrate the intercellular signaling mechanisms.
Materials and methods
Preparation of APS APS were purchased from the Gracia Chemical Technology Co, Chengdu, China. APS were diluted to 10 mg/mL in M199 culture medium containing 10% FBS.
Reagents
Anti-ICAM-1, VCAM-1, NF-κB, phosphorylated-NF-κB, IκBα, phosphorylated-IκBα, Bax, Bcl-2, and MCP-1 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Recombinant human TNF-α was obtained from Peprotech (Rocky Hill, NJ, USA). Secondary antibody against rabbit or goat was purchased from Cell Signaling Technology (Danvers, MA, USA). Unless otherwise indicated, all chemicals were purchased from Sigma (St Louis, CA, USA) or Amresco (Solon, OH, USA).
Cell culture
Human umbilical cords were obtained from healthy donors from whom we received informed consent. HUVECs were isolated from fresh umbilical veins using the procedure described by Jaffe et al [13] and cultured in M199 containing 20% fetal bovine serum, 2 mmol/L glutamine, antibiomycins (10 μmol/L penicillin G and 10 μmol/L streptomycin) at 37 °C in a humidified 5%-CO 2 atmosphere. HUVECs at passages 3-5 were used in the current study.
TNF-α treatment
HUVECs were pretreated with APS for 4 h and then treated with the indicated concentrations of TNF-α for 24 h in 2% FBS medium. The cells were lysed in lysis buffer (Santa Cruz Biotechnology, CA, US), and the samples were then sonicated and centrifuged at 15 000×g for 20 min. The lysates were subjected to Western blotting with specific antibodies.
Western blotting analysis
Cell lysates were analyzed with SDS-PAGE and electrotransfered to PVDF membranes. Membranes were then blocked with 1% bovine serum albumin for 1 h and incubated with specific antibodies for 2 h. After five washes in TBST (containing 0.1% Tween 20 in TBS), the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies in TBST for 1 h. The bands were detected by chemiluminescence detection agents. Blot densitometry was performed, and the bands were analyzed with ImageJ software.
Cell viability assay
Cell viability was examined by the MTT assay according to the instructions of the manufacturer. HUVECs (5000 cells/ well) were plated onto 96-well plates. HUVECs were pretreated with APS for 4 h and then treated with the indicated concentrations of TNF-α for 24 h. All assays were performed in triplicate. The cells were incubated with 0.5 mg/mL 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenylterazolium bromide for 4 h, and the absorbance at 490 nm was measured, as described previously [14] . The MTT kit was purchased from Roche Applied Science (Indianapolis, Indiana).
Hoechst 33342 staining Nuclear fragmentation was detected by incubating fixed cells (70% alcohol and 30% acetone) in 10 mmol/L Hoechst 33342, as previously described [15] . A total of 500-700 cells in 10 randomly chosen fields from each dish were counted to determine the percentage of apoptotic nuclei. Each data point is the result of 5000-7000 cells of 4-8 independent experiments.
In situ detection of reactive oxygen species (ROS) production To evaluate cell ROS production in situ, living HUVECs were stained with 10 μmol/L DHE (Sigma) for 30 min in a dark humidified chamber at 37 °C. ROS generation was labeled with red fluorescence and visualized by fluorescence microscopy, as previously described [16] .
Adhesion assay for monocytes and HUVECs
HUVECs were cultured in 6-well plates in M199 with 20% FBS for 48 h to obtain 90%-95% confluence and were then stimulated with 40 ng/mL TNF-α for 12 h. The human monocyte cell line U937 was incubated in the RPMI-1640 medium with 10% FBS and 50 µg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide at 37 °C for 2 h. The treated HUVECs were washed and co-cultured with a suspension of prepared U937 cells (1×10 6 cells/mL) for 30 min and then washed 3 times with fresh medium 1640. Non-adherent U937 cells were removed by washing. Adherent cells were incubated in 400 μL DMSO at 37 °C for 10 min, and the absorbance at 490 nm was measured.
Immunofluorescence of NF-κB NF-κB expression in HUVECs was detected by immunofluorescence as described previously [17] . Cells were seeded onto sterilized cover slips placed in a 6-well tissue culture plate. After being treated with TNF-α for 8 h, the cells were fixed for 15 min in 4% (w/v) paraformaldehyde/PBS and made permeable by the addition of 0.2% Triton X-100/PBS for 15 min. Blocking solution was added and incubated overnight at 4 °C, and anti-NF-κB p65 antibody was then added to each well for 2 h at 37 °C. After washing, Alexa 488-conjugated anti-rabbit IgG antibody was added and incubated for 0.5 h at 37°C. Cells were then incubated with Hoechst 33342 for 20 min to stain the nuclei. NF-κB p65 was imaged by a fluorescence microscope (BX60; Olympus, Ina, Japan). NF-κB p65 was observed as green fluorescence and the nucleus as blue fluorescence. 
Results
APS inhibit TNF-α-induced ICAM-1 and VCAM-1 expression Activation of endothelial cells by TNF-α has been known to upregulate the expression of adhesion molecules, such as ICAM-1 and VCAM-1. We first determined the concentration of TNF-α that induced HUVEC injury and adhesive molecule upregulation. As shown in Figure 1A , 40 ng/mL TNF-α enhanced the expression of several adhesion molecules, including ICAM-1 and VCAM-1. Next, we evaluated adhesion molecule expression at multiple time points ( Figure  1B ). To be consistent with our previous finding, 40 ng/mL TNF-α was used in this experiment. Thus, we examined whether APS could suppress the upregulation of ICAM-1 and VCAM-1 induced by TNF-α in HUVECs. As shown in Figure  1C , 40 ng/mL TNF-α increased ICAM-1 and VCAM-1 expression at 12 h, while pretreatment with APS abrogated TNF-α-induced ICAM-1 and VCAM-1 expression in a concentrationdependent manner. In particular, HUVEC pretreatment with 10 µg/mL APS significantly decreased ICAM-1 and VCAM-1 expression by 58.37% and 43.54%, respectively, relative to the control (P<0.01). The results indicate that APS suppress the expression of adhesion molecules induced by TNF-α.
APS attenuate the reduced HUVEC viability and increased apoptosis induced by TNF-α Mounting evidence has demonstrated that TNF-α can reduce cell viability and induce apoptosis, which contribute to the development of atherosclerosis. Cultured HUVECs treated with TNF-α showed a significant reduction in cell viability compared to the control (Figure 2A ). HUVEC pretreatment with 10 µg/mL APS strongly enhanced the cell viability compared to treatment with TNF-α alone (P<0.05). Moreover, the apoptotic effect of TNF-α was further manifested by TNF-α-induced increases in chromatin condensation and fragmentation, as revealed in Hoechst 33342 nuclear staining ( Figure  2B ). Accordingly, chromatin condensation and fragmentation in HUVECs pre-treated with APS drastically decreased with increased cell density. The results suggest that pre-treatment with APS can relieve the reduced HUVEC viability and increased apoptosis induced by TNF-α.
APS block TNF-α-induced oxidative stress and adhesion function damage in HUVECs
Atherosclerosis is associated with increased intracellular oxidative stress [18] . Oxidative stress can lead to adhesion function damage of HUVECs. TNF-α is believed to play a role in ROS production in injured endothelium. Therefore, we examined the inhibitory effects of APS on ROS production. As shown in Figure 3A , treatment of HUVECs with 40 ng/mL TNF-α for 12 h significantly increased intracellular ROS production as measured by dihydroethidium. Remarkably, TNF-α-induced ROS generation was significantly inhibited when HUVECs were pretreated with APS at concentrations of 10 µg/mL for 4 h. As shown in Figure 3B , the adhesion function of HUVECs treated by TNF-α for 12 h was significantly damaged; however, the effect was inhibited by pretreatment with APS at concentrations of 10 µg/mL for 4 h. These results indicate that APS can markedly inhibit the oxidative stress and adhesion APS downregulate the expression of adhesion molecules by inhibiting NF-κB activation NF-κB is known to regulate the expression of inflammatory proteins such as ICAM-1 and VCAM-1 in many types of cells. IκBα is the main regulator of NF-κB activation. Inactive NF-κB, bound to its inhibitor IκBα as a complex, is restricted to the cytoplasm. IκBα phosphorylation results in its ubiquitination and degradation; NF-κB is then released from the NF-κB-IκBα complex and translocated to the nucleus. Because we found that APS inhibited the ICAM-1 and VCAM-1 expression induced by TNF-α, we speculated that APS might affect NF-κB activation. Therefore, intracellular activation of NF-κB and IκBα was examined by Western blotting. As shown in Figure 4 , ICAM-1 and VCAM-1 were upregulated after stimulation by 40 ng/mL TNF-α, which was accompanied by NF-κB and IκBα activation. Pretreatment with 10 µg/mL APS prevented the upregulation of ICAM-1 and VCAM-1 and decreased the levels of phosphorylated NF-κB and IκBα in TNF-α-treated HUVECs. In addition, APS attenuated TNF-α-induced Bax expression in HUVECs. Immunofluorescence was used to analyze NF-κB translocation. As shown in Figure  5 , in unstimulated cells, NF-κB was predominantly localized in the cytoplasm, whereas in cells stimulated with TNF-α, NF-κB was almost completely translocated to the nucleus. However, in TNF-α-stimulated cells, pretreatment with 10 µg/mL APS led to the localization of NF-κB in the cytoplasm. The results reveal that APS suppress the activation of NF-κB and IκBα, leading to reduced adhesion molecule expression.
Discussion
Although the beneficial effects of APS have been known for years, this is the first study to demonstrate the protective effects of APS on TNF-α-impaired endothelial adhesion functions and to evaluate the associated mechanism. The major finding of the present study was that pretreatment with APS significantly suppressed ICAM-1 and VCAM-I expression in HUVECs stimulated by TNF-α. The activation of NF-κB and IκBα was decreased and oxidative stress and apoptosis in HUVECs were inhibited by the administration of APS. Inflammation is involved in the initiation, rupture, and thrombosis of atherosclerotic plaques. TNF-α is involved in nearly every step of inflammation [19] . During the early stages of atherosclerosis, inflammatory cell recruitment plays a central role [20] . TNF-α is a key cytokine in the recruitment and activation of inflammatory cells. ICAM-1 and VCAM-1 play a major role in the initiation of early atherosclerosis [21] , preferentially contributing to monocyte adhesion [22] . Inhibition of the inflammatory response is widely known to be beneficial in the early stages of atherosclerosis [23, 24] . Our results showed ICAM-1 and VCAM-1 expression increased in TNF-α-treated HUVECs, and this upregulation of ICAM-1 and VCAM-1 was significantly suppressed by pretreatment with APS in a con- The literature demonstrates that the intracellular signaling initiated by TNF-α is mediated through reactive oxygen intermediates [25] . Furthermore, oxidative stress can result in adhesion function damage, cell survival and apoptosis, which is mediated through apoptosis-associated proteins such as Bax and Bcl-2. In the present study, we found that TNF-α could increase intracellular ROS production, Bax and cell adhesion molecule expression and decrease Bcl-2 expression in HUVECs. Normal cell adhesion function and cell viability were drastically impaired. However, APS significantly attenuated TNF-α-induced oxidative stress and adhesion function damage in HUVECs by inhibiting NF-κB activation and regulating Bax and Bcl-2 expression. Although the signal transduction mechanism was not completely investigated in the present study, a significant decrease in ROS production and There are ample data suggesting that TNF-α increases the binding of NF-κB to its recognition site in the VCAM-1 promoter, promoting its expression and, subsequently, monocyte adhesion to vascular endothelial cells. Recently, reports have shown that both VCAM-1 and ICAM-1 expression are regulated by the TNF-α-mediated NF-κB signaling pathway [26] . In the present study, we observed the degradation of IκBα in the cytoplasm and activation of NF-κB in HUVECs by Western blotting. The TNF-α-induced increase in IκBα degradation in concert with NF-κB p65 activation was inhibited by pretreatment with APS. These findings indicate that APS strongly inhibits NF-κB activation and p65 translocation into the nucleus. In conclusion, we demonstrated that APS suppressed TNF-α-induced phosphorylation of IκBα and NF-κB activation, leading to the downregulation of adhesion molecules and a protective effect on the adhesion function of HUVECs.
In summary, the results of this study demonstrate that the endothelial dysfunction induced by TNF-α, which is associated with the upregulation of adhesion molecules, reduced viability and apoptosis, and elevated ROS generation and adhesion function damage in HUVECs, can be reversed by pretreatment with APS. APS have a preventive effect against endothelial dysfunction by inhibiting oxidative stress, improving endothelial survival and preventing adhesion function damage. Moreover, APS also regulated TNF-α production in endothelial cells (see the Supplementary Data). Therefore, our present findings indicate some novel pharmacological activity of APS, which might be used as a target in the prevention and treatment of endothelial cell injury-related diseases.
